Papsidero L D, Nemoto T, Croghan G A, Chu T M
Cancer Res. 1984 Oct;44(10):4653-7.
A quantitative immunoassay procedure has been constructed to evaluate levels of ductal carcinoma antigen recognized by murine McAb F36/22. Using this method, 3% of 64 apparently healthy individuals and 13% of 40 patients with benign breast disease expressed serum antigen levels above 70 units/ml. Greater than 50% of 116 patients with clinical evidence of breast cancer demonstrated circulating ductal carcinoma antigen levels above 70 units/ml. Patients with ductal carcinomas of other sites, including prostate and gastrointestinal tumors, also demonstrated elevated levels of antigen (11 and 27%, respectively). The incidence of elevated serum ductal carcinoma antigen levels correlated significantly with the incidence of intratumoral antigen expression. Lectin binding, molecular weight, and density measurements indicated that circulating antigen occurs as a high-molecular-weight glycoprotein with mucin-like characteristics.
已构建一种定量免疫测定程序来评估鼠单克隆抗体F36/22识别的导管癌抗原水平。使用该方法，64名表面健康个体中有3%以及40名乳腺良性疾病患者中有13%的血清抗原水平高于70单位/毫升。116名有乳腺癌临床证据的患者中，超过50%的人循环导管癌抗原水平高于70单位/毫升。其他部位的导管癌患者，包括前列腺癌和胃肠道肿瘤患者，也显示出抗原水平升高（分别为11%和27%）。血清导管癌抗原水平升高的发生率与肿瘤内抗原表达的发生率显著相关。凝集素结合、分子量和密度测量表明，循环抗原以具有粘蛋白样特征的高分子量糖蛋白形式存在。
